Literature DB >> 27959738

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Kenneth B Gordon1, Jean-Frederic Colombel2, Dana S Hardin3.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27959738     DOI： 10.1056/NEJMc1610828

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  [Treatment of chronic pruritus-what is new?]

Authors:  C Zeidler; M Metz; S Steinke; S Ständer
Journal:  Hautarzt       Date:  2018-08       Impact factor: 0.751

Review 2.  Langerhans Cells: Sensing the Environment in Health and Disease.

Authors:  Julie Deckers; Hamida Hammad; Esther Hoste
Journal:  Front Immunol       Date:  2018-02-01       Impact factor: 7.561

Review 3.  Emerging targeted therapies for plaque psoriasis - impact of ixekizumab.

Authors:  Tiana Kazemi; Benjamin Farahnik; John Koo; Kourosh Beroukhim
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-04-21

Review 4.  Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy.

Authors:  Deeti J Pithadia; Kelly A Reynolds; Erica B Lee; Wilson Liao; Jashin J Wu
Journal:  Ther Adv Chronic Dis       Date:  2019-08-12       Impact factor: 5.091

5.  Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.

Authors:  Johan Burisch; Wolfgang Eigner; Stefan Schreiber; Daniel Aletaha; Wolfgang Weninger; Michael Trauner; Walter Reinisch; Neeraj Narula
Journal:  PLoS One       Date:  2020-05-27       Impact factor: 3.240

Review 6.  Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon.

Authors:  Alessio Mylonas; Curdin Conrad
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561

7.  Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor.

Authors:  M Gooderham; B E Elewski; D M Pariser; H Sofen; A M Mendelsohn; S J Rozzo; Q Li
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-05-08       Impact factor: 6.166

Review 8.  IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.

Authors:  Esther von Stebut; Wolf-Henning Boehncke; Kamran Ghoreschi; Tommaso Gori; Ziya Kaya; Diamant Thaci; Andreas Schäffler
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

9.  Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients.

Authors:  Han Cao; Shengmin Su; Qi Yang; Yunchen Le; Lihong Chen; Mengyan Hu; Xiaoyu Guo; Jie Zheng; Xia Li; Yunqiu Yu
Journal:  Lipids Health Dis       Date:  2021-02-18       Impact factor: 3.876

10.  Severe de novo Ulcerative Colitis following Ixekizumab Therapy.

Authors:  Jobin Philipose; Moiz Ahmed; Pretty S Idiculla; Stephen M Mulrooney; Vivek V Gumaste
Journal:  Case Rep Gastroenterol       Date:  2018-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.